Drug Profile

VX 264

Alternative Names: VX-264

Latest Information Update: 09 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vertex Pharmaceuticals
Class Antihypercalcaemics; Stem cell therapies
Mechanism of Action Pancreatic beta cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Type 1 diabetes mellitus

Most Recent Events

28 Mar 2025 Efficacy and adverse events data from a phase I/II trial in Type 1 diabetes mellitus released by Vertex Pharmaceuticals
16 May 2023 Vertex Pharmaceuticals initiates phase I/II clinical trial in Type 1 diabetes mellitus in Canada(Parenteral) (NCT05791201)
16 May 2023 Phase-I/II clinical trials in Type 1 diabetes mellitus in Switzerland, USA, United Kingdom, Italy, Germany and England (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com